10-K: Ocular Therapeutix Reports Increased Losses Amid AXPAXLI Progress

Ocular Therapeutix's 2025 annual report reveals widening net losses and declining DEXTENZA revenue, despite significant advancements in its AXPAXLI clinical programs and a substantial capital raise.

Summary

• Net loss for the year ended December 31, 2025, was $265.9 million, an increase from $193.5 million in 2024, contributing to an accumulated deficit of $1,157.0 million.
• Product revenue, primarily from DEXTENZA, decreased by 18.3% to $51.8 million in 2025 from $63.5 million in 2024, attributed to Medicare reimbursement caps, rebates, and MIPS inclusion.
• Research and development expenses significantly increased to $197.1 million in 2025 from $127.6 million in 2024, driven by the progression of AXPAXLI's SOL and HELIOS registrational programs.
• Selling and marketing expenses rose to $53.9 million in 2025 from $41.6 million in 2024, primarily due to the expansion of the commercial team and pre-commercial activities for AXPAXLI.
• General and administrative expenses increased to $64.4 million in 2025 from $60.7 million in 2024, partly due to personnel-related costs and facility expenses.
• Cash and cash equivalents stood at $737.1 million as of December 31, 2025, with outstanding debt of $82.5 million under the Barings Credit Facility.
• The SOL-1 Phase 3 clinical trial for wet AMD maintains an exceptional subject retention rate, with all subjects completing Week 52 visits and re-dosing, and no safety signals identified by the independent data and safety monitoring committee.
• Topline data for the SOL-R Phase 3 clinical trial for wet AMD is now expected in the first quarter of 2027, an acceleration from previous guidance.
• The HELIOS-3 superiority clinical trial for non-proliferative diabetic retinopathy (NPDR) was initiated in November 2025, targeting a broad label in diabetic retinal disease.
• DEXTENZA received supplemental NDA approval in April 2025 for use in pediatric patients for ocular inflammation and pain following ophthalmic surgery, and for ocular itching associated with allergic conjunctivitis in pediatric patients aged 2 years and older.
• A $445.6 million net capital raise was completed in October 2025 through an underwritten public offering of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While clinical pipeline advancements for AXPAXLI are promising and significant capital was raised, the substantial increase in net losses and decline in DEXTENZA product revenue indicate operational challenges and a worsening financial trajectory.

Positives

• AXPAXLI's SOL-1 Phase 3 trial for wet AMD shows exceptional subject retention and per-protocol treatment rescues, with no safety signals identified to date.
• Topline data for the SOL-R Phase 3 trial for wet AMD is now expected in Q1 2027, accelerating from previous guidance of H1 2027.
• Initiation of the HELIOS-3 Phase 3 trial for NPDR in November 2025 marks significant progress in targeting a broad label for diabetic retinal disease.
• DEXTENZA received supplemental FDA approval in April 2025 for pediatric use in post-surgical ocular inflammation and pain, and for allergic conjunctivitis in patients aged 2 years and older, expanding its market.
• The ELUTYX hydrogel technology has a strong safety profile, used in over five million patients across eight FDA-approved treatments since 1992, with DEXTENZA showing adverse events in approximately 2 of every 10,000 patients.
• Successful completion of a pilot repeat-dose sub-study for OTX-TIC 26g showed it was generally well tolerated with no new safety concerns, suggesting potential for repeat dosing without implant stacking.
• A significant capital raise of $445.6 million net in October 2025 substantially increased cash and cash equivalents to $737.1 million, extending the funding runway into 2028.

Negatives

• Net loss significantly increased to $265.9 million in 2025 from $193.5 million in 2024, indicating worsening financial performance.
• Accumulated deficit reached $1,157.0 million as of December 31, 2025, highlighting a history of substantial losses.
• Product revenue from DEXTENZA decreased by 18.3% year-over-year to $51.8 million in 2025, primarily due to Medicare reimbursement caps, increased rebates and discounts, and inclusion in MIPS.
• Gross-to-net provisions for DEXTENZA increased to 51.6% of gross sales in 2025 from 38.5% in 2024, with expectations for this trend to continue or increase further in 2026.
• Significant increase in research and development expenses ($69.5 million year-over-year) and selling and marketing expenses ($12.3 million year-over-year) contributes to higher operating losses.
• Uncertainty remains regarding FDA acceptance of a single registrational trial (SOL-1) for AXPAXLI's wet AMD NDA, potentially delaying approval or requiring additional costly trials.
• The company depends heavily on a small number of specialty distributors and in-market customers for DEXTENZA revenue, with three SDs accounting for 75% of total revenue in 2025, posing concentration risk.

Risks

• Inability to raise additional funds through equity or debt financings or other arrangements when needed, potentially leading to delays, reductions, or termination of product development or commercialization efforts.
• Significant indebtedness ($82.5 million principal outstanding) under the Barings Credit Facility, which may limit cash flow for business needs and could accelerate in an event of default.
• Dependence on the success of product candidate AXPAXLI and commercial product DEXTENZA; failure to obtain marketing approval for AXPAXLI or successfully commercialize DEXTENZA would materially harm the business.
• Clinical trials of product candidates, including AXPAXLI, may not be successful, leading to additional costs, delays, or inability to complete development and commercialization.
• Unforeseen events in clinical trials (e.g., enrollment delays, serious adverse events, negative results, regulatory disagreements) could delay or prevent marketing approval or commercialization.
• FDA may not accept a new drug application for AXPAXLI for wet AMD based on a single registrational trial (SOL-1), even if data are positive, or may deny such application.
• Reliance on single-site manufacturing facilities for DEXTENZA and product candidates, and single-source suppliers for certain materials, poses risks of disruption, supply shortages, and increased costs.
• DEXTENZA and future approved product candidates may become subject to less favorable pricing regulations, third-party coverage or reimbursement practices, or healthcare reform initiatives, harming business.
• Inability to establish and maintain adequate sales, marketing, and distribution capabilities, or gain market acceptance by physicians, patients, and third-party payors, would materially impair revenue generation.
• Inability to retain key executives and attract, retain, and motivate qualified personnel could impede research, development, and commercialization objectives.
• Competition from generic, biosimilar, and branded versions of existing drugs, as well as novel therapies (gene therapy, sustained-release implants), could reduce market share and profitability.
• Ongoing review and extensive regulation of approved products, with potential for withdrawal of approval, fines, or other sanctions for non-compliance.
• Potential dilution of stockholders' ownership interests if additional capital is raised through equity offerings, or restrictive covenants if raised through debt financing.
• Volatility in stock price due to clinical trial results, regulatory developments, competition, and other factors, potentially leading to substantial losses for stockholders.
• Risk of product liability exposure related to the use of product candidates in clinical trials and commercially sold products, potentially leading to substantial liabilities not fully covered by insurance.
• Challenges in protecting intellectual property, including potential invalidation of patents, infringement by competitors, and costly litigation.
• Failure to comply with obligations in intellectual property licenses (e.g., Incept agreement) could result in loss of important rights.
• Claims by third parties of misappropriation of intellectual property or trade secrets, leading to litigation, significant expenses, and distraction of management.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, personnel losses, government shutdowns) could hinder timely guidance and approval of product candidates.
• Compliance with global privacy and data security requirements (e.g., GDPR, CCPA, PADFA) could result in additional costs, liabilities, and restrictions on data processing.

Future Outlook

The company intends to submit a New Drug Application (NDA) for AXPAXLI for wet AMD based on Week 52 data from the SOL-1 trial, leveraging the 505(b)(2) pathway to potentially shorten the review timeline by up to two months. Development plans and regulatory strategy for AXPAXLI in diabetic retinal disease will be refined based on FDA discussions regarding the wet AMD pathway. The SOL-X long-term extension study for wet AMD is planned for initiation in Q2 2026, and the HELIOS-2 trial for diabetic retinal disease may be conducted if needed. The company is currently evaluating next steps for the OTX-TIC program. Expects DEXTENZA unit growth to continue, with selling and marketing expenses increasing for AXPAXLI's potential commercial launch.

Management Comments

• Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer, certified that the Annual Report on Form 10-K fully complies with Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and fairly presents the financial condition and results of operations.
• Jason Robins, Interim Chief Financial Officer, certified the compliance and fair presentation of the financial statements.
• Management believes existing cash and cash equivalents as of December 31, 2025, will fund planned operating expenses, debt service, and capital expenditures into 2028, while observing a minimum liquidity covenant of $20.0 million under the Barings Credit Agreement.
• Management believes current and available cash resources are sufficient to get through potential approval of AXPAXLI for wet AMD by the FDA, but additional funding will likely be required to support its commercialization, if approved.
• Management believes clinicians are adjusting to the impact of MIPS, and together with increased sales efforts directed towards HOPDs, DEXTENZA unit growth is expected to continue.

Industry Context

StockSavvy.ai notes that Ocular Therapeutix operates in a highly competitive ophthalmology market, particularly for retinal diseases, where anti-VEGF therapies like Eylea, Lucentis, and Vabysmo are standard. The company's ELUTYX hydrogel technology aims to address the significant unmet need for longer-duration therapies to reduce treatment burden, a key trend in the industry. The focus on sustained-release axitinib (AXPAXLI) positions the company against emerging gene therapies and other sustained-release TKI implants from competitors like Eyepoint Pharmaceuticals and Glaukos, as well as established players like Roche. The market for exudative retinal diseases is estimated to reach $9.4 billion in U.S. annual revenues by 2025, indicating substantial opportunity but also intense competition for market share.

Comparison to Industry Standards

• DEXTENZA's reported adverse events of approximately 2 in every 10,000 patients since launch demonstrate a favorable safety profile for its ELUTYX technology, aligning with high safety standards for ophthalmic treatments.
• AXPAXLI's design for a duration of six months or longer aims to significantly reduce treatment burden compared to current anti-VEGF standard-of-care drugs (e.g., Eylea, Lucentis, Vabysmo) which typically require injections every six to eight weeks, or as frequently as every four weeks, with some newer options like Vabysmo and Eylea HD offering dosing as infrequently as every 16 weeks for a proportion of patients.
• The use of an ordinal primary endpoint (2-step DRSS change status) in the HELIOS program for diabetic retinal disease is a novel approach, potentially allowing for smaller, shorter, and less expensive trials compared to traditional binary endpoints used in other DR trials.
• AXPAXLI's preclinical pharmacokinetic data showing sustained axitinib concentrations through 12 months, well above the IC50 for VEGFR-2 in cynomolgus monkey retina tissue and choroid/RPE tissues, suggests a competitive advantage in continuous VEGF receptor inhibition compared to therapies with fluctuating drug levels.
• The company faces competition from other sustained-release TKI implants (e.g., Eyepoint Pharmaceuticals' DURAVYU with vorolanib, Glaukos' Retina-XR platform with axitinib) and gene therapies (e.g., 4D Molecular Therapeutics' 4D-150, Adverum Biotechnologies, RegenxBio) which are also in various stages of development for wet AMD and diabetic retinal disease, indicating a crowded and innovative competitive landscape.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any material legal proceedings, nor are any material legal proceedings threatened.
• Previously faced securities class action litigation in 2017 and 2018 related to stock price decline, which were resolved in the company's favor but were costly and distracting.
• In 2020, the PTAB determined that all claims of a third-party patent related to intracanalicular inserts were invalid, a decision affirmed by the United States Court of Appeals for the Federal Circuit in November 2021, with the appeal period having lapsed.

Related Party Transactions

• Engaged Boston Image Reading Center LLC (BIRC) for clinical development services; Nadia Waheed, CMO, is a Director of BIRC. Incurred $761 thousand in fees in 2025.
• Engaged i2Vision, Inc. (affiliated with Jeffrey Heier, CSO, and Peter Kaiser, CDO) for clinical advancement services for AXPAXLI. Recorded a net credit of $(121) thousand in 2025 for services previously expensed.
• Engaged Wilmer Cutler Pickering Hale and Dorr LLP for legal services; Christopher White, former CBO, is the brother of a partner. Incurred $1,080 thousand in fees in 2024 while considered a related party.

Stakeholder Impact

• Shareholders face increased dilution risk from recent and potential future equity offerings to fund operations and commercialization.
• Employees benefit from continued investment in R&D and potential commercialization success, but also face risks associated with the company's financial losses and the competitive biotechnology industry.
• Customers (healthcare providers, patients) may benefit from new ophthalmic therapies like AXPAXLI if approved, offering reduced treatment burden for chronic conditions.
• Suppliers and creditors face risks related to the company's significant losses and dependence on additional financing, though current liquidity is strong due to recent capital raises.

Next Steps

• Present Week 52 results for the SOL-1 trial at the 49th Macula Society Annual Meeting (February 25-28, 2026).
• Submit a New Drug Application (NDA) for AXPAXLI for wet AMD based on SOL-1 Week 52 data, pending favorable results and FDA interactions, potentially using the 505(b)(2) pathway.
• Initiate the SOL-X long-term extension study of AXPAXLI for wet AMD in Q2 2026.
• Report topline data from the SOL-R Phase 3 clinical trial in Q1 2027.
• Refine development plans and regulatory strategy for AXPAXLI for diabetic retinal disease based on anticipated discussions with the FDA regarding the wet AMD pathway.
• Potentially initiate the HELIOS-2 trial for diabetic retinal disease, if needed, to support a superiority label.
• Continue to evaluate next steps for the OTX-TIC program.
• Scale up commercialization and manufacturing capabilities for AXPAXLI, including transforming the 15 Crosby Drive facility into a commercial manufacturing facility.
• Advance pre-commercialization activities for AXPAXLI, expanding sales, marketing, and distribution capabilities.

Key Dates

Recommendation

Ocular Therapeutix presents a mixed investment profile. While the company has made significant clinical progress with its lead candidate AXPAXLI, including accelerated timelines for key data readouts and a clear regulatory strategy, and has substantially bolstered its cash position through recent capital raises, its financial performance shows concerning trends. Net losses are widening, and DEXTENZA product revenue is declining due to market and reimbursement pressures. The success of AXPAXLI's NDA submission and subsequent commercialization is critical but remains uncertain, and the company will require further funding for full commercialization. Given the strong pipeline advancements balanced against persistent operational losses and revenue challenges, a 'hold' recommendation is appropriate for investors to monitor AXPAXLI's regulatory and commercial trajectory.

Keywords

AXPAXLI, DEXTENZA, ELUTYX, Wet AMD, Diabetic Retinal Disease, NPDR, Ocular Hypertension, Glaucoma, Biopharmaceutical, Clinical Trials, Phase 3, FDA Approval, SEC Filing, 10-K, Ophthalmology, Drug Delivery, Hydrogel, Anti-VEGF, Tyrosine Kinase Inhibitor, Axitinib, Travoprost, Dexamethasone, Reimbursement, Intellectual Property, Capital Raise, Net Loss, Product Revenue